Printer Friendly
The Free Library
19,607,059 articles and books
Member login
User name  
Password 
 
Join us Forgot password?

Bausch & Lomb Completes Sale of Charles River Laboratories to DLJ Merchant Banking Partners II, L.P.


ROCHESTER, N.Y.--(BUSINESS WIRE)--Sept. 29, 1999--

Bausch & Lomb (NYSE NYSE

See: New York Stock Exchange
:BOL BOL Bolivia (ISO Country code)
BOL Books Online
BOL Bole (SIL code, Nigeria)
BOL Bill Of Lading
BOL Beginning Of Line
BOL Best Of Luck
BOL Buzz Out Loud
BOL Bruin Online
BOL Beginning Of Life
) has completed the sale of Charles River Charles River

River, eastern Massachusetts, U.S. The longest river wholly in the state, it flows into Boston Bay after a course of about 80 mi (130 km). Navigable for about 7 mi (11 km), its estuary separates the cities of Boston and Cambridge.
 Laboratories, its Wilmington, Mass.-based research laboratory animal and service business, to DLJ Merchant Banking Partners DLJ Merchant Banking Partners (DLJMB) is a LBO-focused private equity firm of Credit Suisse. DLJMB has offices in New York, London and Los Angeles. External links
  • DLJ Merchant Banking Partners
 II, L.P., (DLJMBP DLJMBP Donaldson, Lufkin & Jenrette Merchant Banking Partners ) an affiliate of the New York-based investment banking firm of Donaldson, Lufkin & Jenrette. DLJMBP acquired the business together with the Charles River Laboratories management team.

The purchase package is comprised of a $400 million cash payment, a $43 million promissory note promissory note, unconditional written promise to pay a certain sum of money at a definite time to bearer or to a specified person on his order. Promissory notes are generally used as evidence of debt. , and Bausch & Lomb is retaining a 12.5 percent minority interest in the divested business. Bausch & Lomb expects to record a pre-tax gain in the range of $280 million, and an after-tax gain in the range of $2.85 per share.

Charles River Laboratories, acquired by Bausch & Lomb in 1984, is the last of the global eye-care company's non-strategic businesses to be divested. Bausch & Lomb is now solely focused on providing technology-based healthcare for the eye.

Bausch & Lomb Incorporated is the preeminent global technology-based healthcare company for the eye, dedicated to helping consumers see, look and feel better through innovative technology and design. Its core businesses include soft and rigid gas permeable gas permeable gas adj (lenses) → luftdurchlässig  contact lenses, lens-care products, ophthalmic surgical and pharmaceutical products. The company is advantaged with some of the most respected brands in the world starting with its name, Bausch & Lomb(R), and including SofLens66(TM), PureVision(TM) Boston(R), ReNu(R), and Storz(R). Founded in 1853 in Rochester, N.Y., where it continues to have its headquarters, the company has pro-forma annual revenues of approximately $1.8 billion and employs approximately 12,000 people in 35 countries. Bausch & Lomb products are available in more than 100 countries around the world. Additional information about the company can be found on Bausch & Lomb's Worldwide Web site at http://www.bausch.com.
COPYRIGHT 1999 Business Wire
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1999, Gale Group. All rights reserved. Gale Group is a Thomson Corporation Company.

 Reader Opinion

Title:

Comment:



 

Article Details
Printer friendly Cite/link Email Feedback
Publication:Business Wire
Date:Sep 29, 1999
Words:301
Previous Article:Waferscale Quadruples SRAM On EasyFLASH MCU Support ICs; World's First ICs With 8-Kbytes of SRAM, 256-Kbytes of Flash and a 3,000 gate CPLD.
Next Article:Calpine Begins Construction of 500-mw Natural Gas Energy Center in Pittsburg, Calif.; Acquisition of Project Development Rights and CEC Licensing...



Related Articles
Tender Offer for DeCrane Shares Completed.
DeCrane Aircraft Holdings Appoints New Chief Financial Officer.
Luxottica Group to Purchase Bausch & Lomb Sunglass Business.
Bausch & Lomb Signs Definitive Agreement to Sell Charles River Laboratories to Global Health Care Partners of DLJ.
Global Health Care Partners and DLJ Merchant Banking Partners II, L.P. to Acquire Pharbil Pharma GmBH.
Global Health Care Partners and DLJ Merchant Banking Partners II, L.P. Announce the Formation of BioPartners S.A.
Vitopel of Argentina and Koppol of Brazil to be acquired by J.P. Morgan Latin America Capital Partners and DLJ Merchant Banking Partners II, L.P.
AT CLOSING NEWS.
Charles River Announces Board of Directors Changes; Credit Rating Upgrade.

Terms of use | Copyright © 2012 Farlex, Inc. | Feedback | For webmasters | Submit articles